PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Duke-NUS study proposes new heart failure treatment targeting abnormal hormone activity

Scientists have discovered that blocking the activity of the hormone glucagon could treat a common and challenging type of heart failure that affects millions worldwide.

Duke-NUS study proposes new heart failure treatment targeting abnormal hormone activity
2024-09-30
(Press-News.org)

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult to treat. The team discovered that the diseased heart cells had high levels of glucagon activity, a pancreatic hormone that raises blood sugar (glucose) levels. Armed with this novel insight, the scientists demonstrated that a drug that blocks the hormone’s activity, can significantly improve heart function.

In heart failure, which is considered a global pandemic, the heart can no longer pump blood effectively. In Singapore, heart failure is a leading cause of death, accounting for 17 per cent of cardiac admissions locally[1]. Globally, an estimated 64 million people live with this condition[2], with HFpEF accounting for around half of the cases[3].

In HFpEF, the heart can pump normally but its muscles are too stiff to relax to re-fill the chambers with blood properly. It is often seen in older adults and people with multiple risk factors including high blood pressure (hypertension), obesity and diabetes. They typically have symptoms such as shortness of breath, fatigue and reduced ability to exercise. This is unlike heart failure with reduced ejection fraction (HFrEF), where the heart muscle is weakened and unable to pump with enough force—therefore, less blood is being pushed into the body.

There have been studies on how the heart is stressed by hypertension and metabolic diseases associated with obesity, such as diabetes, but these have been done in isolation of each other. This latest study, which was published in Circulation Research, addresses this gap by taking into account both stressors, revealing for the first time, the molecular pathway that contributes to HFpEF progression.

In pre-clinical studies, the team of scientists, which included collaborators from the University of Cincinnati College of Medicine, University of California Los Angeles, University of Toronto and University of North Carolina School of Medicine, investigated how stress from hypertension affected lean hearts versus diabetic/obese ones. In their findings, the lean models developed heart failure with reduced ejection fraction (HFrEF), typically observed in hypertensive patients. The obese models however, developed heart failure with preserved ejection fraction (HFpEF), proving that a combination of stressors give rise to the disease and providing a good model for further studies.

Using advanced single-cell RNA-sequencing technologies, the scientists were then able to study the expression of every detected gene in every single heart cell, allowing them to uncover specific genetic variations in cells associated with HFpEF. The scientists found that in the obese models, the most active genes were the ones driving the activity of glucagon.

Professor Wang Yibin, Director of the Cardiovascular & Metabolic Disorders Programme at Duke-NUS and senior author of the study, said:

“Under stress conditions such as high blood pressure and metabolic disorders like obesity and diabetes, we found that glucagon signalling becomes excessively active in heart cells. This heightened activity contributes to the development of heart failure with preserved ejection fraction (HFpEF) by increasing heart stiffness and impairing its ability to relax and fill with blood.”

The team then tested a drug that blocks the glucagon receptor in a pre-clinical model of HFpEF and found significant improvements in heart function, including reduced heart stiffness, enhanced relaxation, improved blood filling capacity and overall better heart performance.

Assistant Professor Chen Gao from the Department of Pharmacology, Physiology and Neurobiology at the University of Cincinnati College of Medicine; and the study’s first author, said:

“Our study shows strong evidence that a glucagon receptor blocker could work well to treat HFpEF. Repurposing this drug, which is already being tested in clinical trials for diabetes, could bypass the lengthy drug development process and provide quicker and more effective relief to millions of heart patients.”

Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, commented:

“With our ageing population, there will likely be more patients with multiple conditions, including heart failure, diabetes and hypertension, presenting a significant challenge to health systems. Uncovering the synergistic impact of such illnesses and their underlying mechanisms is key to better understanding the complex process of heart failure and developing an effective treatment for the disease.”  

The researchers hope to work with clinical partners to conduct clinical trials to test the glucagon receptor blocker in humans with HFpEF. If these succeed, it could become one of the first effective treatments for this challenging condition, significantly improving the quality of life for millions worldwide.

Duke-NUS is a global leader in medical education and a biomedical research powerhouse, combining basic scientific research with translational know-how to bring a better understanding to common diseases, like heart failure, and develop new treatment approaches to improve the lives of people in Singapore and beyond.

 

[1] Chan WX, Lin W and Wong RCC. Transitional care to reduce heart failure readmission rates in South East Asia. Cardiac Failure Review 2016; 2: 85–9. 

[2] Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular research. 2022 Dec 1;118(17):3272-87.

[3] Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14:591–602. doi:10.1038/nrcardio.2017.65

 

###

About Duke-NUS Medical School                    

Duke-NUS is Singapore’s flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.   

For more information, please visit www.duke-nus.edu.sg 

END


[Attachments] See images for this press release:
Duke-NUS study proposes new heart failure treatment targeting abnormal hormone activity

ELSE PRESS RELEASES FROM THIS DATE:

People who experience side effects from cranial radiation therapy may recover full neurocognitive function within months

2024-09-29
WASHINGTON, September 29, 2024 — A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three large, phase III clinical trials. Recovery was more likely for people treated with conformal, or highly targeted, radiation techniques, compared to standard whole-brain treatment. The findings will be presented today at the American Society for Radiation Oncology (ASTRO) ...

Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

2024-09-29
WASHINGTON, September 29, 2024 — A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.  “We’ve found a therapy with a meaningful signal for effectiveness and safety for people with refractory meningioma, a condition with no ...

American Academy of Pediatrics promotes shared reading starting in infancy as a positive parenting practice with lifelong benefits

2024-09-29
ORLANDO, Fla.--The American Academy of Pediatrics encourages parents and caregivers to read aloud with their newborns and young children as an opportunity to foster loving, nurturing relationships during a critical time of brain development, and recommends that pediatricians support families with guidance and books at well-child visits, according to an updated policy statement. The policy statement, “Literacy Promotion: An Essential Component of Primary Care Pediatric Practice,” marks the first update in AAP recommendations since 2014. Given the extraordinary amount of research in this area, an accompanying ...

Unexpected human behaviour revealed in prisoner's dilemma study: Choosing cooperation even after defection

2024-09-28
The study also examined the impact of different game structures, such as simultaneous versus alternating decision-making, and the option of voluntary participation. The results showed that these variations significantly influence participants' cooperation rate.   The research reveals that people tend to cooperate even after being defected, which contradicts many traditional game theory models. "This finding is particularly fascinating because it suggests that humans are more forgiving and cooperative than previously thought," said Dr. Hitoshi Yamamoto, the study's lead researcher.   The ...

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease
2024-09-27
An innovative analysis of shared segments within the genome — an indication of distant “relatedness” — has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal heart rhythms, fainting and sudden cardiac death.   The findings, reported in the journal Nature Communications, illustrate the feasibility of the new approach developed by researchers at Vanderbilt University Medical Center to detect undiagnosed carriers of rare ...

UCLA at ASTRO: Predicting response to chemoradiotherapy in rectal cancer, 2-year outcomes of MRI-guided radiotherapy for prostate cancer, impact of symptom self-reporting during chemoradiation and mor

2024-09-27
UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation therapies will present data on the latest radiation oncology research and clinical trial results at the 66th annual American Society for Radiation Oncology (ASTRO) meeting in Washington D.C., Sept. 29 to Oct. 2. The annual meeting, which is the leading meeting in radiation oncology, will feature 23 abstracts from UCLA investigators that highlight key areas of radiation oncology, including new research in subspecialties ranging from survivorship, lung cancer/thoracic malignancies, physics, sarcoma, gastrointestinal cancer, genitourinary cancer, gynecological ...

Estimated long-term benefits of finerenone in heart failure

2024-09-27
About The Study: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.  Corresponding Author: To contact the corresponding author, Scott D. Solomon, M.D., email ssolomon@rics.bwh.harvard.edu. To access the embargoed study: Visit our For The Media website at ...

MD Anderson launches first-ever academic journal: Advances in Cancer Education & Quality Improvement

MD Anderson launches first-ever academic journal: Advances in Cancer Education & Quality Improvement
2024-09-27
The University of Texas MD Anderson Cancer Center today announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement (ACE-QI). The journal will publish research, training program summaries and quality improvement interventions for the oncology provider community. The open-access, peer-reviewed journal will feature research and professional perspectives focused on training health care providers to meet myriad challenges around prevention, diagnosis, treatment and survivorship in cancer care. “We envision this journal as a catalyst for critical conversations across the cancer care continuum," said Joshua Kuban, M.D., associate ...

Penn Medicine at the 2024 ASTRO Annual Meeting

2024-09-27
PHILADELPHIA – Leading experts in radiation therapy from Penn Medicine’s Abramson Cancer Center and the Perelman School of Medicine will present new results from clinical trials and research studies at the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting, which will be held at the Walter E. Washington Convention Center in Washington, D.C., Sept. 29 through Oct. 2, 2024. At the meeting, Neha Vapiwala, MD, FACR, FASTRO, FASCO, the Eli Glatstein Professor in Radiation Oncology, will take office as president-elect of ASTRO as the first Penn faculty member to lead the premier society ...

Head and neck, meningioma research highlights of University of Cincinnati ASTRO abstracts

2024-09-27
University of Cincinnati Cancer Center experts will present research at the American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 29 through Oct. 2.  Osteoradionecrosis more common in patients with head and neck cancer that requires partial jaw removal  Following radiation treatment for head and neck cancer, some patients can experience osteoradionecrosis (ORN) when an area of exposed bone fails to heal after a three-month period.  “ORN of the mandible and maxilla (jaw bones) can be very debilitating, as it often causes severe pain, fistula formation, infection and susceptibility to fractures,” ...

LAST 30 PRESS RELEASES:

Workforce diversity is key to advancing One Health

Genome Research publishes a special issue on innovations in computational biology

A quick and easy way to produce anode materials for sodium-ion batteries using microwaves

‘Inside-out’ galaxy growth observed in the early universe

Protein blocking bone development could hold clues for future osteoporosis treatment

A new method makes high-resolution imaging more accessible

Tiny magnetic discs offer remote brain stimulation without transgenes

Illuminating quantum magnets: Light unveils magnetic domains

Different types of teenage friendships critical to wellbeing as we age, scientists find

Hawaii distillery project wins funding from Scottish brewing and distilling award

Trinity researchers find ‘natural killer’ cells that live in the lung are ready for a sugar rush

$7 Million from ARPA-H to tackle lung infections through innovative probiotic treatment

Breakdancers may risk ‘headspin hole’ caused by repetitive headspins, doctors warn

Don’t rely on AI chatbots for accurate, safe drug information, patients warned

Nearly $10M investment will expand and enhance stroke care in Minnesota, South Dakota

Former Georgia, Miami coach Mark Richt named 2025 Paul “Bear” Bryant Heart of a Champion

$8.1M grant will allow researchers to study the role of skeletal stem cells in craniofacial bone diseases and deformities

Northwestern to promote toddler mental health with $11.7 million NIMH grant

A new study finds that even positive third-party ratings can have negative effects

Optimizing inhibitors that fight antibiotic resistance

New Lancet Commission calls for urgent action on self-harm across the world

American Meteorological Society launches free content for weather enthusiasts with “Weather Band”

Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy

How your skin tone could affect your meds

NEC Society, Cincinnati Children's, and UNC Children’s announce NEC Symposium in Chicago

Extreme heat may substantially raise mortality risk for people experiencing homelessness

UTA professor earns NSF grants to study human-computer interaction

How playing songs to Darwin’s finches helped UMass Amherst biologists confirm link between environment and the emergence of new species

A holy grail found for catalytic alkane activation

Galápagos finches could be singing a different song after repeated drought—one that leads to speciation

[Press-News.org] Duke-NUS study proposes new heart failure treatment targeting abnormal hormone activity
Scientists have discovered that blocking the activity of the hormone glucagon could treat a common and challenging type of heart failure that affects millions worldwide.